Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.65 |
| ▸ | CNR2 | P34972 | 3/20 | 0.65 |
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18670586 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL4183234 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL7211379 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL886852 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL9951849 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL6665064 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL16400196 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL5884581 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL15364951 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL7638596 | 0.98 | CNR1 (0.67) | CNR1CNR2FAAHALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2921171-B1 | Ophthalmic, intra-articular or intravesical preparations containing N-acyl-ethanolamines | EPITECH GROUP S P A (IT) | 2019-10-16 | — | — | EP | claimed |
| US-20180021281-A1 | LIPID FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND OTHER BIOACTIVE AGENTS | SCIADONICS, INC. | 2018-01-25 | — | — | US | claimed |
| WO-2018017667-A1 | LIPID FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND OTHER BIOACTIVE AGENTS | SCIADONICS, INC. (US) | 2018-01-25 | — | — | WO | claimed |
| US-20160128961-A1 | DIETARY OMEGA-3 FATTY ACID DERIVED GLYCEROPHOSPHOLIPIDS TO TREAT NEUROPATHIC PAIN | UNIV LOMA LINDA (US) | 2016-05-12 | — | — | US | claimed |
| EP-3003331-A1 | DIETARY OMEGA-3 FATTY ACID DERIVED GLYCEROPHOSPHOLIPIDS TO TREAT NEUROPATHIC PAIN | Loma Linda University (US) | 2016-04-13 | — | — | EP | claimed |
| US-20150265551-A1 | OPHTHALMIC, INTRA-ARTICULAR OR INTRAVESICAL PREPARATIONS CONTAINING N-ACYL-ETHANOLAMINES | Epitech Group S.r.I. (IT) | 2015-09-24 | — | — | US | claimed |
| EP-2921171-A1 | Ophthalmic, intra-articular or intravesical preparations containing N-acyl-ethanolamines | Epitech Group S.r.l. (IT) | 2015-09-23 | — | — | EP | claimed |
| WO-2014197880-A1 | DIETARY OMEGA-3 FATTY ACID DERIVED GLYCEROPHOSPHOLIPIDS TO TREAT NEUROPATHIC PAIN | LOMA LINDA UNIVERSITY (US) | 2014-12-11 | — | — | WO | claimed |
| EP-4568643-A1 | COMPOSITIONS COMPRISING AMAROUCIAXANTHIN A ESTERS AND USES THEREOF | Gat Therapeutics S.L. (ES) | 2025-06-18 | — | — | EP | disclosed |
| CN-119744163-A | Composition comprising AMAROUCIAXANTHIN A esters and use thereof | 加特治疗有限公司 | 2025-04-01 | — | — | CN | disclosed |
| EP-4458352-A1 | EICOSAPENTAENOIC ACID ESTER DERIVATIVES FOR THE TREATMENT OF OBESITY | Technische Universität Dresden (DE) | 2024-11-06 | — | — | EP | disclosed |
| US-20240301449-A1 | PRODUCTION OF CANNABINOID GLYCOSIDE COMPOUNDS IN CELL CULTURE | TRAIT BIOSCIENCES INC (US) | 2024-09-12 | — | — | US | disclosed |
| WO-2024013306-A1 | COMPOSITIONS COMPRISING AMAROUCIAXANTHIN A ESTERS AND USES THEREOF | GAT THERAPEUTICS, S.L. (ES) | 2024-01-18 | — | — | WO | disclosed |
| EP-4306101-A1 | COMPOSITIONS COMPRISING AMAROUCIAXANTHIN A ESTERS AND USES THEREOF | Gat Therapeutics S.L. (ES) | 2024-01-17 | — | — | EP | disclosed |
| EP-1482920-A1 | N-ACYL-PHOSPHATIDYL-ETHANOLAMINES AND/OR MIXTURES OF N-ACYL-ETHANOLAMINES WITH PHOSPHATIDIC ACIDS OR LYSOPHOSPHATIDIC ACIDS | Hunza di Pistolesi Elvira & C. S.a.S. (IT) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003068210-A1 | N-ACYL-PHOSPHATIDYL-ETHANOLAMINES AND/OR MIXTURES OF N-ACYL-ETHANOLAMINES WITH PHOSPHATIDIC ACIDS OR LYSOPHOSPHATIDIC ACIDS | HUNZA DI PISTOLESI ELVIRA & C. S.A.S. (IT) | 2003-08-21 | — | — | WO | disclosed |
| EP-0952841-A4 | SITE-SPECIFIC BIOMOLECULAR COMPLEXES | MOLECULAR STRUCTURAL BIOTECHNO (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6005004-A | POLYLYSINE, POLYARGININE AND POLYORNITHINE BIMOLECULAR COMPLEXES | MOLECULAR / STRUCTURAL BIOTECHNOLOGIES, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0952841-A1 | SITE-SPECIFIC BIOMOLECULAR COMPLEXES | MOLECULAR/STRUCTURAL BIOTECHNOLOGIES, INC. (US) | 1999-11-03 | — | — | EP | disclosed |
| WO-1996004001-A1 | SITE-SPECIFIC BIOMOLECULAR COMPLEXES | MOLECULAR/STRUCTURAL BIOTECHNOLOGIES, INC. (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150265551-A1 | OPHTHALMIC, INTRA-ARTICULAR OR INTRAVESICAL PREPARATIONS CONTAINING N-ACYL-ETHANOLAMINES | UACA, AADAC, PHOSPHO1 | CNR1 316/4885CNR2 242/4885FAAH 496/4885 |
| US-20240301449-A1 | PRODUCTION OF CANNABINOID GLYCOSIDE COMPOUNDS IN CELL CULTURE | CNR2, CNR1, UGCG | CNR1 2/4885CNR2 1/4885FAAH 4/4885 |
| US-20180021281-A1 | LIPID FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND OTHER BIOACTIVE AGENTS | FAAH, ELOVL1, DGKA | CNR1 38/4885CNR2 34/4885FAAH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.